Lytic anti-CD45 mAb or anti-CD45 mAb RIT with standard chemotherapy have been tested in the clinic for conditioning of patients with hematological malignancies with the dual benefit that hematological malignancies are CD45+ (63, 64, 73, 74). Here, PTPRC is linked to hematologic disorder.